Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You forgetting DR. KENDALL !!
Check-Cap Appoints Alex Ovadia as Chief Executive OfficerFont size: A | A | A
8:00 AM ET 2/26/18 | Dow Jones
Global Operations and R&D Veteran Brings Focus to C-Scan(R) Commercial Pathway
ISFIYA, Israel, Feb. 26, 2018 /PRNewswire/ --
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan(R), an ingestible capsule for preparation-free, colorectal cancer screening, today announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. Prior to this appointment, Mr. Ovadia served as Check-Cap's Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition.
Mr. Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare -- CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as Chief Executive Officer. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE Mark approval a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, Chief Executive Officer of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan(R), the first capsule-based system for preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "look forward" and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts
Vivian Cervantes
PCG Advisory
646-863-6274
Vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
meirav@bauerg.com
View original content:http://www.prnewswire.com/news-releases/check-cap-appoints-alex-ovadia-as-chief-executive-officer-300603955.html
SOURCE Check-Cap Ltd.
TGLO gonna be a Game Changer imo !
I think you better strap in..just my opinion
Check-Cap Appoints Alex Ovadia as Chief Executive OfficerFont size: A | A | A
8:00 AM ET 2/26/18 | Dow Jones
Global Operations and R&D Veteran Brings Focus to C-Scan(R) Commercial Pathway
ISFIYA, Israel, Feb. 26, 2018 /PRNewswire/ --
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan(R), an ingestible capsule for preparation-free, colorectal cancer screening, today announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. Prior to this appointment, Mr. Ovadia served as Check-Cap's Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition.
Mr. Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare -- CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as Chief Executive Officer. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE Mark approval a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, Chief Executive Officer of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan(R), the first capsule-based system for preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "look forward" and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts
Vivian Cervantes
PCG Advisory
646-863-6274
Vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
meirav@bauerg.com
View original content:http://www.prnewswire.com/news-releases/check-cap-appoints-alex-ovadia-as-chief-executive-officer-300603955.html
SOURCE Check-Cap Ltd.
CHEK News !!
Check-Cap Appoints Alex Ovadia as Chief Executive OfficerFont size: A | A | A
8:00 AM ET 2/26/18 | Dow Jones
Global Operations and R&D Veteran Brings Focus to C-Scan(R) Commercial Pathway
ISFIYA, Israel, Feb. 26, 2018 /PRNewswire/ --
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan(R), an ingestible capsule for preparation-free, colorectal cancer screening, today announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. Prior to this appointment, Mr. Ovadia served as Check-Cap's Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition.
Mr. Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare -- CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as Chief Executive Officer. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE Mark approval a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, Chief Executive Officer of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan(R), the first capsule-based system for preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "look forward" and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts
Vivian Cervantes
PCG Advisory
646-863-6274
Vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
meirav@bauerg.com
View original content:http://www.prnewswire.com/news-releases/check-cap-appoints-alex-ovadia-as-chief-executive-officer-300603955.html
SOURCE Check-Cap Ltd.
CHEK News !!
Check-Cap Appoints Alex Ovadia as Chief Executive OfficerFont size: A | A | A
8:00 AM ET 2/26/18 | Dow Jones
Global Operations and R&D Veteran Brings Focus to C-Scan(R) Commercial Pathway
ISFIYA, Israel, Feb. 26, 2018 /PRNewswire/ --
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan(R), an ingestible capsule for preparation-free, colorectal cancer screening, today announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. Prior to this appointment, Mr. Ovadia served as Check-Cap's Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition.
Mr. Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare -- CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as Chief Executive Officer. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE Mark approval a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, Chief Executive Officer of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan(R), the first capsule-based system for preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "look forward" and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts
Vivian Cervantes
PCG Advisory
646-863-6274
Vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
meirav@bauerg.com
View original content:http://www.prnewswire.com/news-releases/check-cap-appoints-alex-ovadia-as-chief-executive-officer-300603955.html
SOURCE Check-Cap Ltd.
CHEK News !!
Check-Cap Appoints Alex Ovadia as Chief Executive OfficerFont size: A | A | A
8:00 AM ET 2/26/18 | Dow Jones
Global Operations and R&D Veteran Brings Focus to C-Scan(R) Commercial Pathway
ISFIYA, Israel, Feb. 26, 2018 /PRNewswire/ --
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan(R), an ingestible capsule for preparation-free, colorectal cancer screening, today announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. Prior to this appointment, Mr. Ovadia served as Check-Cap's Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition.
Mr. Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare -- CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as Chief Executive Officer. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE Mark approval a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, Chief Executive Officer of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan(R), the first capsule-based system for preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "look forward" and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts
Vivian Cervantes
PCG Advisory
646-863-6274
Vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
meirav@bauerg.com
View original content:http://www.prnewswire.com/news-releases/check-cap-appoints-alex-ovadia-as-chief-executive-officer-300603955.html
SOURCE Check-Cap Ltd.
Watch "C Scan" on YouTube
www://twitter.com/checkcap
Boom time about to begin imo
Stay tuned I think this has a major run in it any day now,it will move fast in my own opinion
I think things are about to look way up this week..just a feeling
All imo
My guess is news right around the corner
all imo
That's what I'm hoping to see, a buyout or big settlement...either would move this stock in a big way in my opinion
Lol..good luck with that
Too funny
The volume over the last month and bid support leeds me to believe otherwise..I'm guessing alot sooner then later...all in my opinion
Bingo!!
How do you mean ?
I'm in CHEK..hoping news brings volume and a move over $1+
WESTLAKE VILLAGE, Calif., Feb. 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM (Eastern Time) on February 27, 2018.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Chief Financial Officer, Steven Binder, Chief Commercial Officer, Pat McCauley and Chief Medical Officer, David Kendall.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 46307898. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4630 7898#. A replay will also be available on MannKind's website for 14 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com
globenewswire.com/news-release/2018/02/23/1386675/0/en/MannKind-Corporation-to-Hold-2017-Fourth-Quarter-and-Full-Year-Financial-Results-Conference-Call-on-February-27-2018.html
Read more: http://mnkd.proboards.com/thread/9597/fourth-quarter-financial-results-conferen#ixzz57wNffAb8
Locked and Loaded !!!
MNKD...Good buying going on...
Imagine the feeling these traders will have if MNKD puts out a killer PR and we gap up huge and they weren't in..priceless ))...imo
PMPG moves fast,we all know that ))..imo
Don't see a need for a reverse split whatsoever..imo
CHEK..eom
Sounds good !!
Me too !
I think patience will be Greatly rewarded here in my opinion
Very well said !!
That Speaks for itself !!
Lol
PMPG...Anytime now and BOOM!! imo
Boomage that much closer imo
It's coming imo
Figure it out for yourself,shorts are gonna be squeezed hard here imo